https://www.nmsgroup.it/dmed-successfully-assisted-italian-nms-groups-parp-inhibitor-to-obtain-clinical-trial-approval/ 2020-12-28T10:59:21+00:00 https://www.nmsgroup.it/nanding-zhao-appointed-ceo-of-nms-group-to-accelerate-the-development-of-the-groups-strategy/ 2020-12-28T11:02:58+00:00 https://www.nmsgroup.it/rozlytrek-roches-first-tumour-agnostic-therapy-approved-in-europe-for-people-with-ntrk-fusion-positive-solid-tumours-and-for-people-with-ros1-positive-advanced-non-small-cell-lung-cancer/ 2020-12-28T11:03:15+00:00 https://www.nmsgroup.it/thermo-fisher-scientific-signs-companion-diagnostic-agreement-with-chugai-pharmaceutical/ 2020-12-28T11:03:28+00:00 https://www.nmsgroup.it/cancer-patients-to-benefit-from-new-histology-independent-treatment/ 2020-12-28T11:03:43+00:00 https://www.nmsgroup.it/cardiff-oncology-data-continues-to-demonstrate-efficacy-durability-and-safety-of-onvansertib-in-patients-with-difficult-to-treat-relapsed-refractory-aml/ 2020-12-28T11:04:04+00:00 https://www.nmsgroup.it/nice-approves-new-rare-lung-cancer-treatment-from-roche-2/ 2020-12-28T11:05:03+00:00 https://www.nmsgroup.it/cardiff-oncology-announces-expanded-access-program-for-onvansertib-in-kras-mutated-metastatic-colorectal-cancer-as-follow-on-to-fast-track-designation/ 2020-12-28T12:14:03+00:00 https://www.nmsgroup.it/chmp-recommends-eu-approval-of-roches-rozlytrek-entrectinib-for-people-with-ntrk-fusion-positive-solid-tumours-and-for-people-with-ros1-positive-advanced-non-small-cell-lung-cancer/ 2020-12-28T12:14:11+00:00 https://www.nmsgroup.it/cardiff-oncology-data-continues-to-demonstrate-efficacy-of-onvansertib-in-patients-with-kras-mutated-metastatic-colorectal-cancer-presented-at-asco/ 2020-12-28T12:14:24+00:00 https://www.nmsgroup.it/cardiff-oncology-announces-fast-track-designation-granted-by-the-fda-to-onvansertib-for-second-line-treatment-of-kras-mutated-colorectal-cancer/ 2020-12-28T12:14:43+00:00 https://www.nmsgroup.it/phase-2-the-battle-continues-and-nms-group-will-keep-protecting-our-nerviano-community/ 2020-12-28T12:14:49+00:00 https://www.nmsgroup.it/cardiff-oncology-enters-agreement-with-poc-capital-to-fund-phase-2-clinical-trial-of-onvansertib-in-kras-mutated-metastatic-colorectal-cancer-mcrc/ 2020-12-28T12:14:54+00:00 https://www.nmsgroup.it/onvansertib-trial-in-kras-mutated-colorectal-cancer-demonstrates-consistent-tumor-regression-across-kras-mutation-subtypes-and-durable-response/ 2020-12-28T12:14:58+00:00 https://www.nmsgroup.it/health-canada-approves-rozlytrek-entrectinib-for-ntrk-gene-fusion-positive-solid-tumours-in-locally-advanced-or-metastatic-patients1/ 2020-12-28T12:15:03+00:00 https://www.nmsgroup.it/nms-group-stand-by-nerviano-first-batch-of-masks-donated-to-the-community/ 2020-12-28T12:15:08+00:00 https://www.nmsgroup.it/xspray-receives-notification-of-manufacturing-approval-and-provides-update-on-clinical-studies/ 2020-12-28T12:15:12+00:00 https://www.nmsgroup.it/chugai-obtains-approval-for-additional-indication-of-rozlytrek-generic-name-entrectinib-for-ros1-fusion-positive-non-small-cell-lung-cancer/ 2020-12-28T12:15:17+00:00 https://www.nmsgroup.it/nms-group-and-the-association-of-chinese-enterprises-in-italy-fighting-coronavirus-covid-19-together/ 2020-12-28T12:15:22+00:00 https://www.nmsgroup.it/nms-group-merger-by-incorporation-of-clioss-s-r-l-into-nms-s-r-l/ 2020-12-28T12:15:51+00:00 https://www.nmsgroup.it/claudio-bernardi-expert-from-accelera-and-nms-group-appointed-industry-representative-of-the-national-expert-committee-for-the-parere-network-by-the-ministry-of-health-in-italy/ 2020-12-28T12:16:05+00:00 https://www.nmsgroup.it/dr-enrico-pesenti-ceo-of-accelera-a-member-of-nms-group-has-co-authored-the-article-entitled-a-tumor-in-host-deb-based-approach-for-modeling-cachexia-and-bevacizumab-resistance-on/ 2020-12-28T12:16:09+00:00 https://www.nmsgroup.it/the-chinese-ambassador-to-italy-li-junhua-led-a-delegation-to-visit-nms-group-in-nerviano-milan-italy/ 2020-12-28T12:16:15+00:00 https://www.nmsgroup.it/nerviano-medical-sciences-announced-today-first-patient-enrolled-in-first-in-human-clinical-trial-of-the-parp-inhibitor-nms-293-in-patients-with-advanced-solid-tumors/ 2020-12-28T12:16:19+00:00 https://www.nmsgroup.it/nms-groups-ceo-attended-china-biomed-innovation-and-investment-conference-in-suzhou-china/ 2020-12-28T12:16:24+00:00 https://www.nmsgroup.it/fda-approves-genentechs-rozlytrek-entrectinib-for-people-with-ros1-positive-metastatic-non-small-cell-lung-cancer-and-ntrk-gene-fusion-positive-solid-tumors/ 2020-12-28T12:16:29+00:00 https://www.nmsgroup.it/nerviano-medical-sciences-presented-its-research-activities-on-antibodies-drug-conjugated-at-the-xxvi-annual-congress-of-the-italian-chemistry-society-division-of-pharmaceutical-chemistry/ 2020-12-28T12:16:33+00:00 https://www.nmsgroup.it/trovagene-announces-initiation-of-enrollment-for-phase-1b-2-clinical-trial-in-kras-mutated-colorectal-cancer-at-leading-comprehensive-cancer-centers/ 2020-12-28T12:16:39+00:00 https://www.nmsgroup.it/nerviano-medical-sciences-attendance-at-the-16th-annual-meeting-of-the-bioinformatics-italian-society/ 2020-12-28T12:16:44+00:00 https://www.nmsgroup.it/japan-becomes-the-first-country-to-approve-roches-personalised-medicine-rozlytrek-entrectinib/ 2020-12-28T12:16:49+00:00 https://www.nmsgroup.it/nerviano-medical-sciences-receives-a-recognition-by-the-italian-chemical-society/ 2020-12-28T12:16:54+00:00 https://www.nmsgroup.it/array-biopharma-announces-braftovi-mektovi-cetuximab-meet-primary-endpoints-of-orr-and-os-in-phase-3-beacon-crc-trial-interim-analysis-for-the-treatment-of-brafv600e-mutant-metastatic-colorectal/ 2020-12-28T12:17:00+00:00 https://www.nmsgroup.it/genentechs-personalized-medicine-entrectinib-shrank-tumors-harboring-ntrk-ros1-or-alk-gene-fusions-in-children-and-adolescents/ 2020-12-28T12:17:04+00:00 https://www.nmsgroup.it/at-aacr-meeting-nerviano-medical-sciences-presents-new-evidences-on-its-own-flt3-kit-csf1r-inhibitor-and-its-activities-on-the-identification-and-characterization-of-atp-mimetic-choline-kinase-inhibit/ 2020-12-28T12:17:09+00:00 https://www.nmsgroup.it/early-data-from-phase-2-trial-indicates-activity-of-onvansertib-in-prostate-cancer-patients-showing-initial-resistance-to-anti-androgen-therapy/ 2020-12-28T12:17:13+00:00 https://www.nmsgroup.it/nerviano-medical-sciences-announces-the-publication-of-the-first-peer-reviewed-article-concerning-nms-p945/ 2020-12-28T12:17:18+00:00 https://www.nmsgroup.it/nms-group-is-the-sponsor-of-the-eighth-edition-of-china-career-day/ 2020-12-28T12:17:28+00:00 https://www.nmsgroup.it/fda-grants-priority-review-to-entrectinib/ 2020-12-28T12:17:32+00:00 https://www.nmsgroup.it/chugai-files-a-new-drug-application-for-a-ros1-trk-inhibitor-entrectinib-for-the-treatment-of-ntrk-fusion-positive-solid-tumors/ 2020-12-28T12:18:07+00:00 https://www.nmsgroup.it/clioss-implements-veeva-vault-clinical-applications-to-streamline-trial-management/ 2020-12-28T12:18:27+00:00 https://www.nmsgroup.it/tiziana-completes-patient-enrollment-in-a-phase-2a-trial-to-evaluate-tolerability-and-anti-tumor-activity-of-milciclib-in-hepatocellular-carcinoma-hcc/ 2020-12-28T12:18:41+00:00 https://www.nmsgroup.it/nms-group-wins-the-capital-elite-china-awards-2018/ 2020-12-28T12:18:47+00:00 https://www.nmsgroup.it/nms-group-announces-collaboration-with-c-p-university-to-promote-academic-exchange-and-cooperation-between-the-two-parties/ 2020-12-28T12:18:52+00:00 https://www.nmsgroup.it/nerviano-medical-sciences-received-a-prestigious-marie-sklodowska-curie-fellowship-under-the-eu-research-and-innovation-programme-horizon-2020/ 2020-12-28T12:18:57+00:00 https://www.nmsgroup.it/xspray-pharma-and-nerpharma-deliver-clinical-trial-material-to-hynap-dasa-study/ 2020-12-28T12:19:03+00:00 https://www.nmsgroup.it/thanks-to-the-outcomes-of-nerviano-medical-sciences-research-on-chordoma-a-phase-ii-study-on-the-activity-of-an-egfr-inhibitor-was-initiated/ 2020-12-28T12:19:09+00:00 https://www.nmsgroup.it/nerviano-medical-sciences-announces-collaboration-and-license-agreement-with-merck-to-discover-small-molecule-inhibitors-of-certain-anticancer-targets/ 2020-12-28T12:19:15+00:00 https://www.nmsgroup.it/he-american-association-for-cancer-research-presents-award-to-a-scientist-from-nerviano-medical-sciences-at-its-annual-meeting/ 2020-12-28T12:19:21+00:00 https://www.nmsgroup.it/nerviano-researchers-contribution-in-building-anticancer-drug-actions-atlas/ 2020-12-28T12:19:27+00:00 https://www.nmsgroup.it/nerviano-medical-sciences-to-present-data-on-several-of-its-pipeline-molecules-at-2018-aacr-annual-meeting/ 2020-12-28T12:19:35+00:00 https://www.nmsgroup.it/sari-announces-closing-of-acquisition/ 2020-12-28T12:19:43+00:00 https://www.nmsgroup.it/nerviano-medical-sciences-announced-clinical-trial-approval-in-china-of-the-parp-inhibitor-nms-293-in-patients-with-advanced-solid-tumors-today/ 2021-02-16T11:10:47+00:00 https://www.nmsgroup.it/nerpharma-and-icrom-sealed-partnership-agreement/ 2021-07-29T17:54:51+00:00 https://www.nmsgroup.it/nms-group-wins-china-awards-for-creating-concrete-values/ 2021-07-29T17:55:24+00:00 https://www.nmsgroup.it/accelera-and-cross-an-integrated-solution-for-pre-clinical-to-clinical-transition/ 2021-08-25T09:01:19+00:00 https://www.nmsgroup.it/accelera-and-biomimx-commercial-agreement/ 2021-08-25T20:19:25+00:00 https://www.nmsgroup.it/entrectinib-inhibitor-nerviano-aifa-italy/ 2021-09-22T08:04:05+00:00 https://www.nmsgroup.it/biotech-week-2021-webinar-in-italian-sviluppo-di-farmaci-in-ambito-oncologico/ 2021-10-01T16:06:42+00:00 https://www.nmsgroup.it/wp-content/uploads/2021/09/Biotech-week.png https://www.nmsgroup.it/cphi-worldwide/ 2021-10-05T16:59:33+00:00 https://www.nmsgroup.it/wp-content/uploads/2021/10/CPhI-NMS-Group.png https://www.nmsgroup.it/topdrugdiscoverydevelopment/ 2021-10-18T09:10:12+00:00 https://www.nmsgroup.it/wp-content/uploads/2021/09/NMS-Group-Certificate.png https://www.nmsgroup.it/wp-content/uploads/2021/09/NMS-PTO-Cover.png https://www.nmsgroup.it/wp-content/uploads/2021/09/NMS-GROUP-Award-Logo.png https://www.nmsgroup.it/entrectinib-the-kinase-inhibitor-drug-invented-and-initially-developed-by-nerviano-medical-sciences-won-the-prix-galien-italia-2021-award-in-the-chemically-synthesized-drugs-category/ 2021-11-05T08:22:04+00:00 https://www.nmsgroup.it/wp-content/uploads/2021/11/medaglie_III_02551.jpg https://www.nmsgroup.it/nerviano-medical-sciences-receives-fda-study-may-proceed-letter-for-first-in-human-phase-1-clinical-trial-under-its-investigational-new-drug-application-for-nms-03602173-a-dual-idh1/ 2022-01-13T10:22:33+00:00 https://www.nmsgroup.it/member-of-european-parliament-isabella-tovaglieri-and-chairman-of-the-health-commission-of-lombardy-region-emanuele-monti-led-delegation-to-visit-nms-group-in-nerviano-lombardy/ 2022-02-08T14:43:48+00:00 https://www.nmsgroup.it/wp-content/uploads/2022/02/NMS-Group-MEP-Tovaglieri-1-scaled.jpg https://www.nmsgroup.it/wp-content/uploads/2022/02/NMS-Group-MEP-Tovaglieri-1-scaled.jpg https://www.nmsgroup.it/wp-content/uploads/2022/02/NMS-Group-MEP-Tovaglieri-2-scaled.jpg https://www.nmsgroup.it/wp-content/uploads/2022/02/20220207_Delegazione-4-scaled.jpg https://www.nmsgroup.it/wp-content/uploads/2022/02/20220207_Delegazione-10-re-scaled.jpg https://www.nmsgroup.it/nms-group-s-p-a-announces-appointment-of-new-ceo-hugues-dolgos-and-new-board-of-directors-and-ceo-of-its-subsidiaries/ 2022-02-08T16:05:13+00:00 https://www.nmsgroup.it/nms-group-s-p-a-announces-resignation-of-angelo-colombo-as-ceo-of-accelera-srl-and-nerpharma-srl-hugues-dolgos-ceo-of-nms-group-s-p-a-appointed-interim-ceo/ 2022-05-05T16:01:51+00:00 https://www.nmsgroup.it/nerviano-medical-sciences-announces-new-organizational-structure-and-management-team-including-key-appointments/ 2022-05-05T17:39:38+00:00 https://www.nmsgroup.it/european-journal-of-cancer-this-month-published-an-article-on-the-fih-study-in-patients-with-solid-tumors-conducted-with-the-mps1-compound-nms-01940153e-discovered-at-nms-srl/ 2022-05-27T16:30:04+00:00 https://www.nmsgroup.it/bryet-health-inc-starts-a-manufacturing-development-agreement-with-nerpharma-for-its-lead-product-candidate-ml-016-against-lung-and-liver-metastases-from-different-type-of-breast-cancer/ 2022-05-31T16:49:15+00:00 https://www.nmsgroup.it/nerviano-medical-sciences-signs-research-agreement-with-universita-del-piemonte-orientale-faculty-of-pharmaceutical-sciences/ 2022-06-28T10:53:11+00:00 https://www.nmsgroup.it/nms-group-s-p-a-has-approved-the-2021-financial-statements-with-positive-outlook-for-2022/ 2022-07-14T17:28:54+00:00 https://www.nmsgroup.it/nerviano-medical-sciences-s-r-l-announces-first-patient-dosed-in-phase-1-clinical-trial-of-nms-812-for-the-treatment-of-relapsed-refractory-multiple-myeloma-mm/ 2022-07-19T10:51:55+00:00 https://www.nmsgroup.it/nerviano-medical-sciences-s-r-l-expends-us-presence/ 2022-08-03T11:47:27+00:00 https://www.nmsgroup.it/nerviano-medical-sciences-s-r-l-announces-collaboration-and-option-to-license-agreement-with-merck-2/ 2022-09-27T09:29:37+00:00 https://www.nmsgroup.it/wp-content/uploads/2022/09/Immagine4.jpg https://www.nmsgroup.it/wp-content/uploads/2022/09/Hugues-Merck-Quote-NMS-Group.jpg https://www.nmsgroup.it/we-are-ict-in-maastricht-2022/ 2022-09-30T16:40:22+00:00 https://www.nmsgroup.it/wp-content/uploads/2022/09/Senza-titolo-1-1-e1663057296297.png https://www.nmsgroup.it/accelera-srl-announces-change-in-board-composition-effective-today/ 2022-10-01T08:06:50+00:00 https://www.nmsgroup.it/nerpharma-srl-announces-change-in-board-composition-effective-today/ 2022-10-01T08:08:29+00:00 https://www.nmsgroup.it/data-on-nms-01940153e-selected-for-oral-presentation-at-34th-eortc-nci-aacr-symposium-on-molecular-targets-and-cancer-therapeutics/ 2022-10-17T08:04:59+00:00 https://www.nmsgroup.it/wp-content/uploads/2022/10/Immagine1.png https://www.nmsgroup.it/nms-group-s-p-a-announced-appointment-of-lincoln-pan-to-board-of-directors/ 2022-10-19T07:33:56+00:00 https://www.nmsgroup.it/wp-content/uploads/2022/10/Immagine2.png https://www.nmsgroup.it/nerviano-medical-sciences-s-r-l-announces-a-poster-presentation-on-nms-03602173-at-34th-eortc-nci-aacr-symposium-on-molecular-targets-and-cancer-therapeutics/ 2022-10-26T07:09:40+00:00 https://www.nmsgroup.it/wp-content/uploads/2022/10/Immagine1-3.png https://www.nmsgroup.it/nerviano-medical-sciences-s-r-l-shared-data-on-nms-01940153e-selected-for-oral-presentation-at-34th-eortc-nci-aacr-symposium-on-molecular-targets-and-cancer-therapeutics/ 2022-10-28T15:01:31+00:00 https://www.nmsgroup.it/wp-content/uploads/2022/10/Immagine2-1.png https://www.nmsgroup.it/wp-content/uploads/2022/10/Immagine1-4.png https://www.nmsgroup.it/nms-01940153e-nms-153-at-34th-eortc-nci-aacr-symposium-on-molecular-targets-and-cancer-therapeutics/ 2022-11-04T11:38:05+00:00 https://www.nmsgroup.it/wp-content/uploads/2022/11/ENA-2022.jpg https://www.nmsgroup.it/wp-content/uploads/2022/11/ENA-2022.jpg https://www.nmsgroup.it/nms-group-s-p-a-names-sidney-shin-yi-dung-as-chief-operating-officer-to-drive-growth/ 2023-01-10T10:23:41+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/01/Immagine1.png https://www.nmsgroup.it/wp-content/uploads/2023/01/Immagine1.png https://www.nmsgroup.it/mps1-nms-01940153e-kinase-inhibitor-shows-clinical-activity-in-primary-liver-cancer/ 2023-01-10T12:10:28+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/01/Immagine1-1.png https://www.nmsgroup.it/wp-content/uploads/2023/01/Immagine1-1.png https://www.nmsgroup.it/nerviano-medical-sciences-strengthens-executive-team-to-maximize-idh1-idh2-inhibitor-asset-terrence-west-mba-joins-as-new-business-virtual-ceo/ 2023-01-13T13:28:29+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/01/terry.png https://www.nmsgroup.it/wp-content/uploads/2023/01/Twest1.jpg https://www.nmsgroup.it/nerviano-medical-sciences-appointed-gergely-balint-msc-to-accelerate-mps1-inhibitor-asset-development/ 2023-02-01T10:41:30+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/02/Immagine2.png https://www.nmsgroup.it/wp-content/uploads/2023/02/GBalint-NMS.jpg https://www.nmsgroup.it/nerviano-medical-sciences-appointed-anders-elm-pedersen-md-phd-dmsc-as-senior-medical-director-to-accelerate-further-the-global-clinical-development-progress/ 2023-03-01T11:56:10+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/03/Immagine1.png https://www.nmsgroup.it/wp-content/uploads/2023/03/Immagine1.png https://www.nmsgroup.it/visit-accelera-team-at-the-sot-2023-annual-meeting-in-nashville-tennessee-march-19-23/ 2023-03-04T16:58:47+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/03/accelera.png https://www.nmsgroup.it/accelera-a-21-congresso-nazionale-sitox-bologna-20-22-febbraio-2023/ 2023-03-04T17:00:01+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/02/Sitox23_accelera_small.png https://www.nmsgroup.it/wp-content/uploads/2023/02/Sitox23_accelera_small.png https://www.nmsgroup.it/accelera-and-cross-an-integrated-solution-for-pre-clinical-to-clinical-transition-2/ 2023-04-04T02:12:03+00:00 https://www.nmsgroup.it/cphi-worldwide-2/ 2023-04-04T02:12:03+00:00 https://www.nmsgroup.it/e-matching/ 2023-04-04T02:12:03+00:00 https://www.nmsgroup.it/bio-japan-2018/ 2023-04-04T02:12:03+00:00 https://www.nmsgroup.it/nordic-life-science-day/ 2023-04-04T02:12:03+00:00 https://www.nmsgroup.it/biomed-mixiii/ 2023-04-04T02:12:03+00:00 https://www.nmsgroup.it/meet-in-italy-for-life-sciences/ 2023-04-04T02:12:03+00:00 https://www.nmsgroup.it/bio-europe-2018/ 2023-04-04T02:12:03+00:00 https://www.nmsgroup.it/bio-spain/ 2023-04-04T02:12:04+00:00 https://www.nmsgroup.it/cell-and-gene-therapy/ 2023-04-04T02:12:04+00:00 https://www.nmsgroup.it/eurotox-congress-of-the-european-society-of-toxicology/ 2023-04-04T02:12:05+00:00 https://www.nmsgroup.it/knowledgeforgrouth/ 2023-04-04T02:12:06+00:00 https://www.nmsgroup.it/biotech-in-life-science-interazione-tra-ricerca-partner-industriali-e-capital-venture-per-accedere-e-accendere-linnovazione/ 2023-04-04T02:12:06+00:00 https://www.nmsgroup.it/using-organ-on-a-chip-technology-to-reduce-animal-testing/ 2023-04-04T02:12:06+00:00 https://www.nmsgroup.it/bio-convention/ 2023-04-04T02:12:06+00:00 https://www.nmsgroup.it/13th-international-symposium-of-the-synthesis-and-application-of-isotoped-and-isotopically-labelled-compounds/ 2023-04-04T02:12:06+00:00 https://www.nmsgroup.it/xvii-national-giqar-congress/ 2023-04-04T02:12:06+00:00 https://www.nmsgroup.it/xybions-34th-annual-pristima-user-group-meeting/ 2023-04-04T02:12:06+00:00 https://www.nmsgroup.it/knowledgeforgrouth/ 2023-04-04T02:12:06+00:00 https://www.nmsgroup.it/bio-korea/ 2023-04-04T02:12:06+00:00 https://www.nmsgroup.it/2-convegno-nazionale-attuazione-dei-principi-di-buona-pratica-di-laboratorio-bpl/ 2023-04-04T02:12:06+00:00 https://www.nmsgroup.it/swiss-biotech-day/ 2023-04-04T02:12:06+00:00 https://www.nmsgroup.it/sitox-2018/ 2023-04-04T02:12:06+00:00 https://www.nmsgroup.it/nc3rs-cardiovascular-showcase-event-and-social-housing-telemetry-workshop/ 2023-04-04T02:12:06+00:00 https://www.nmsgroup.it/bstp-continuing-education-symposium-11-lymphoid-haematopoietic-systems-span/ 2023-04-04T02:12:07+00:00 https://www.nmsgroup.it/ebf-strategy-meeting/ 2023-04-04T02:12:07+00:00 https://www.nmsgroup.it/sot-2018/ 2023-04-04T02:12:07+00:00 https://www.nmsgroup.it/ebf-european-bioanalysis-forum/ 2023-04-04T02:12:07+00:00 https://www.nmsgroup.it/bio-europe/ 2023-04-04T02:12:07+00:00 https://www.nmsgroup.it/meet-in-italy/ 2023-04-04T02:12:07+00:00 https://www.nmsgroup.it/biojapan-2017/ 2023-04-04T02:12:07+00:00 https://www.nmsgroup.it/eu-netval/ 2023-04-04T02:12:07+00:00 https://www.nmsgroup.it/xxxv-conferenza-nazionale-di-citrometria/ 2023-04-04T02:12:07+00:00 https://www.nmsgroup.it/ebf-focus-workshop-industry-input-into-ich-m10-experimental-data-as-the-cornerstone-for-a-science-driven-bioanalytical-guideline/ 2023-04-04T02:12:07+00:00 https://www.nmsgroup.it/sps-safety-pharmacology-society-annual-meeting/ 2023-04-04T02:12:07+00:00 https://www.nmsgroup.it/bio-25th-symposium-on-glycosaminoglycans/ 2023-04-04T02:12:07+00:00 https://www.nmsgroup.it/nls-nordic-life-science-days/ 2023-04-04T02:12:07+00:00 https://www.nmsgroup.it/eurotox-congress-of-the-european-society-of-toxicology-2/ 2023-04-04T02:12:08+00:00 https://www.nmsgroup.it/the-23rd-iis_ced-workshop/ 2023-04-04T02:12:08+00:00 https://www.nmsgroup.it/2672/ 2023-04-04T02:12:08+00:00 https://www.nmsgroup.it/ebf-adc-training-day-and-focus-workshop/ 2023-04-04T02:12:08+00:00 https://www.nmsgroup.it/2674/ 2023-04-04T02:12:08+00:00 https://www.nmsgroup.it/labiotech-refresh-berlin-2017/ 2023-04-04T02:12:08+00:00 https://www.nmsgroup.it/57-simposio-afi-for-life-sciences/ 2023-04-04T02:12:08+00:00 https://www.nmsgroup.it/pharmacokinetic-pharmacodynamic-modeling-of-continous-and-categorical-data-in-nonmem/ 2023-04-04T02:12:08+00:00 https://www.nmsgroup.it/xxvi-congresso-nazionale-giqar/ 2023-04-04T02:12:08+00:00 https://www.nmsgroup.it/meet2win/ 2023-04-04T02:12:08+00:00 https://www.nmsgroup.it/swiss-biotech-day-2/ 2023-04-04T02:12:08+00:00 https://www.nmsgroup.it/biokorea-2017-and-forum-bilaterale-biopharma-italia-korea-2017/ 2023-04-04T02:12:09+00:00 https://www.nmsgroup.it/biotech-pharma-summit-2017/ 2023-04-04T02:12:09+00:00 https://www.nmsgroup.it/bio-europe-spring-2017/ 2023-04-04T02:12:09+00:00 https://www.nmsgroup.it/ebf-strategy-meeting-2/ 2023-04-04T02:12:09+00:00 https://www.nmsgroup.it/bio-fit/ 2023-04-04T02:12:09+00:00 https://www.nmsgroup.it/ksns/ 2023-04-04T02:12:09+00:00 https://www.nmsgroup.it/ebf-7th-european-bioanalysis-forum/ 2023-04-04T02:12:09+00:00 https://www.nmsgroup.it/bio-europe-2/ 2023-04-04T02:12:09+00:00 https://www.nmsgroup.it/sps/ 2023-04-04T02:12:09+00:00 https://www.nmsgroup.it/bio-japan-2016/ 2023-04-04T02:12:09+00:00 https://www.nmsgroup.it/21st-workshop-of-the-iis-ced/ 2023-04-04T02:12:09+00:00 https://www.nmsgroup.it/meet-in-italy-for-life-sciences-2/ 2023-04-04T02:12:09+00:00 https://www.nmsgroup.it/14th-congress-of-the-european-society-of-toxicologic-pathology/ 2023-04-04T02:12:09+00:00 https://www.nmsgroup.it/eurotox/ 2023-04-04T02:12:10+00:00 https://www.nmsgroup.it/43rd-annual-meeting-of-the-japanese-society-of-toxicology/ 2023-04-04T02:12:10+00:00 https://www.nmsgroup.it/14th-european-meeting-of-the-international-society-for-the-study-of-xenobiotics/ 2023-04-04T02:12:10+00:00 https://www.nmsgroup.it/55a-simposium-afi-associazione-farmaceutici-industria/ 2023-04-04T02:12:10+00:00 https://www.nmsgroup.it/bio-convention-2016/ 2023-04-04T02:12:10+00:00 https://www.nmsgroup.it/biomed-2016/ 2023-04-04T02:12:10+00:00 https://www.nmsgroup.it/ksns-korean-society-nonclinical-studies/ 2023-04-04T02:12:10+00:00 https://www.nmsgroup.it/bio-korea-2016/ 2023-04-04T02:12:10+00:00 https://www.nmsgroup.it/swiss-biotech-day-3/ 2023-04-04T02:12:15+00:00 https://www.nmsgroup.it/bio-europe-spring/ 2023-04-04T02:12:15+00:00 https://www.nmsgroup.it/ebf-strategic-meeting-and-annual-meeting/ 2023-04-04T02:12:15+00:00 https://www.nmsgroup.it/society-of-toxicology-sot/ 2023-04-04T02:12:16+00:00 https://www.nmsgroup.it/31st-japanese-toxicology-pathology-annual-meeting/ 2023-04-04T02:12:17+00:00 https://www.nmsgroup.it/ksns-2/ 2023-04-04T02:12:17+00:00 https://www.nmsgroup.it/european-bioanalysis-forum/ 2023-04-04T02:12:17+00:00 https://www.nmsgroup.it/bio-europe-3/ 2023-04-04T02:12:17+00:00 https://www.nmsgroup.it/bio-japan-2015/ 2023-04-04T02:12:17+00:00 https://www.nmsgroup.it/21st-workshop-of-the-iis-ced-2/ 2023-04-04T02:12:19+00:00 https://www.nmsgroup.it/meet-in-italy-for-life-sciences-3/ 2023-04-04T02:12:20+00:00 https://www.nmsgroup.it/2713/ 2023-04-04T02:12:20+00:00 https://www.nmsgroup.it/eurotox-2/ 2023-04-04T02:12:20+00:00 https://www.nmsgroup.it/42nd-annual-meeting-of-the-japanese-society-of-toxicology/ 2023-04-04T02:12:20+00:00 https://www.nmsgroup.it/13th-european-meeting-of-the-international-society-for-the-study-of-xenobiotics/ 2023-04-04T02:12:20+00:00 https://www.nmsgroup.it/55a-simposium-afi-associazione-farmaceutici-industria-2/ 2023-04-04T02:12:20+00:00 https://www.nmsgroup.it/ksns-korean-society-nonclinical-studies-2/ 2023-04-04T02:12:20+00:00 https://www.nmsgroup.it/adme-predictive-toxicology/ 2023-04-04T02:12:20+00:00 https://www.nmsgroup.it/society-of-toxicology-sot-2/ 2023-04-04T02:12:21+00:00 https://www.nmsgroup.it/sitox/ 2023-04-04T02:12:21+00:00 https://www.nmsgroup.it/strategic-meeting-and-annual-meeting/ 2023-04-04T02:12:21+00:00 https://www.nmsgroup.it/jstp-31st-japanese-toxicology-pathology-annual-meeting/ 2023-04-04T02:12:21+00:00 https://www.nmsgroup.it/outsourcing-preclinical-development/ 2023-04-04T02:12:21+00:00 https://www.nmsgroup.it/7th-european-bioanalysis-forum/ 2023-04-04T02:12:26+00:00 https://www.nmsgroup.it/26th-eortc-nci_aacr/ 2023-04-04T02:12:27+00:00 https://www.nmsgroup.it/bio-europe-4/ 2023-04-04T02:12:27+00:00 https://www.nmsgroup.it/bio-spain-2014/ 2023-04-04T02:12:27+00:00 https://www.nmsgroup.it/eurotox-3/ 2023-04-04T02:12:32+00:00 https://www.nmsgroup.it/nordic-life-science-days/ 2023-04-04T02:12:33+00:00 https://www.nmsgroup.it/42nd-meeting-of-the-european-teratology-society/ 2023-04-04T02:12:34+00:00 https://www.nmsgroup.it/2nd-cutting-edge-pathology-congress/ 2023-04-04T02:12:34+00:00 https://www.nmsgroup.it/european-bioanalysis-forum-ebf-focus-workshop-taking-tiered-approach-to-the-next-level/ 2023-04-04T02:12:34+00:00 https://www.nmsgroup.it/54a-simposium-afi-associazione-farmaceutici-industria/ 2023-04-04T02:12:35+00:00 https://www.nmsgroup.it/ddi-2014-4th-international-workshop-on-regulatory-requirements-and-current-scientific-aspects-on-the-preclinical-and-clinical-investigation-of-drug-drug-interactions/ 2023-04-04T02:12:40+00:00 https://www.nmsgroup.it/20th-international-symposium-on-mdo-microsomes-and-drug-oxidations/ 2023-04-04T02:12:40+00:00 https://www.nmsgroup.it/european-society-for-autoradiography/ 2023-04-04T02:12:40+00:00 https://www.nmsgroup.it/dmdg-tissue-analysis-the-matrix-revisited/ 2023-04-04T02:12:41+00:00 https://www.nmsgroup.it/adme-predictive-toxicology-2/ 2023-04-04T02:12:42+00:00 https://www.nmsgroup.it/deutsche-biotechnologietage-2014/ 2023-04-04T02:12:42+00:00 https://www.nmsgroup.it/swiss-biotech-day-4/ 2023-04-04T02:12:43+00:00 https://www.nmsgroup.it/aacr-annual-meeting/ 2023-04-04T02:12:43+00:00 https://www.nmsgroup.it/society-of-toxicology-sot-3/ 2023-04-04T02:12:45+00:00 https://www.nmsgroup.it/bio-europe-spring-2/ 2023-04-04T02:12:46+00:00 https://www.nmsgroup.it/early-drug-development-summit-2013/ 2023-04-04T02:12:46+00:00 https://www.nmsgroup.it/ebf-6th-european-bioanalysis-forum/ 2023-04-04T02:12:46+00:00 https://www.nmsgroup.it/bio-europe-2013/ 2023-04-04T02:12:46+00:00 https://www.nmsgroup.it/19th-workshop-on-the-international-isotope-society-ced-central-european-division/ 2023-04-04T02:12:46+00:00 https://www.nmsgroup.it/navigating-biologics-clinical-trials/ 2023-04-04T02:12:46+00:00 https://www.nmsgroup.it/sps-annual-meeting/ 2023-04-04T02:12:46+00:00 https://www.nmsgroup.it/estp-11th-european-congress-of-toxicologic-pathology/ 2023-04-04T02:12:46+00:00 https://www.nmsgroup.it/eurotox-4/ 2023-04-04T02:12:46+00:00 https://www.nmsgroup.it/generics-and-biosimilars-in-central-and-eastern-europe/ 2023-04-04T02:12:46+00:00 https://www.nmsgroup.it/53a-simposio-afi-associazione-farmaceutici-industria/ 2023-04-04T02:12:46+00:00 https://www.nmsgroup.it/14th-drug-discovery-drug-development-leaders-summit-2013/ 2023-04-04T02:12:47+00:00 https://www.nmsgroup.it/deutsche-biotechnologietage-2013/ 2023-04-04T02:12:47+00:00 https://www.nmsgroup.it/adme-predictive-toxicology-3/ 2023-04-04T02:12:47+00:00 https://www.nmsgroup.it/adme-predictive-toxicology-4/ 2023-04-04T02:12:47+00:00 https://www.nmsgroup.it/discovery-summit-europe/ 2023-04-04T02:12:47+00:00 https://www.nmsgroup.it/society-of-toxicology-sot-4/ 2023-04-04T02:12:47+00:00 https://www.nmsgroup.it/swiss-biotech-day-5/ 2023-04-04T02:12:47+00:00 https://www.nmsgroup.it/2nd-biosimilars-congregation-2013/ 2023-04-04T02:12:47+00:00 https://www.nmsgroup.it/outsourcing-preclinical-development-5th-annual-meeting/ 2023-04-04T02:12:47+00:00 https://www.nmsgroup.it/ebf-5th-european-bioanalysis-forum/ 2023-04-04T02:12:47+00:00 https://www.nmsgroup.it/bio-europe-2012/ 2023-04-04T02:12:47+00:00 https://www.nmsgroup.it/odd-outsourcing-drug-development/ 2023-04-04T02:12:47+00:00 https://www.nmsgroup.it/3rd-annual-innovations-in-phase-1-clinical-development/ 2023-04-04T02:12:48+00:00 https://www.nmsgroup.it/estp-12th-european-congress-of-toxicologic-pathology/ 2023-04-04T02:12:48+00:00 https://www.nmsgroup.it/iis-synthesis-and-applications-of-isotopes-and-isotopically-labelled-compounds/ 2023-04-04T02:12:48+00:00 https://www.nmsgroup.it/eurotox-5/ 2023-04-04T02:12:48+00:00 https://www.nmsgroup.it/12th-european-issx-meeting/ 2023-04-04T02:12:48+00:00 https://www.nmsgroup.it/13th-drug-discovery-drug-development-leaders-summit-2012/ 2023-04-04T02:12:48+00:00 https://www.nmsgroup.it/page-2012/ 2023-04-04T02:12:48+00:00 https://www.nmsgroup.it/deutsche-biotechnologietage-2012/ 2023-04-04T02:12:48+00:00 https://www.nmsgroup.it/sitox-2/ 2023-04-04T02:12:48+00:00 https://www.nmsgroup.it/bio-europe-spring-3/ 2023-04-04T02:12:48+00:00 https://www.nmsgroup.it/discovery-summit-europe-2/ 2023-04-04T02:12:49+00:00 https://www.nmsgroup.it/adme-predictive-toxicology-5/ 2023-04-04T02:12:49+00:00 https://www.nmsgroup.it/society-of-toxicology-sot-5/ 2023-04-04T02:12:49+00:00 https://www.nmsgroup.it/clinical-outsourcing-partnerships-for-biologics-biosimilars/ 2023-04-04T02:12:49+00:00 https://www.nmsgroup.it/nerviano-medical-sciences-s-r-l-announces-clinical-data-on-nms-03592088-selected-for-oral-presentation-at-aacr-annual-meeting-2023/ 2023-04-04T14:16:48+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/04/logo1.png https://www.nmsgroup.it/nms-group-certified-as-workplace-that-promotes-health-initiatives-again-in-2022/ 2023-04-05T07:37:43+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/04/cop.png https://www.nmsgroup.it/wp-content/uploads/2023/04/NMS1.jpg https://www.nmsgroup.it/wp-content/uploads/2023/04/recognition-22.jpg https://www.nmsgroup.it/nerviano-medical-sciences-s-r-l-to-present-new-preclinical-data-for-nms-812-and-nms-0963-at-the-american-association-for-cancer-research-aacr-2023-annual-meeting/ 2023-04-05T08:29:26+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/04/logo3.png https://www.nmsgroup.it/dr-claudio-bernardi-has-been-appointed-as-a-member-of-the-rentic-national-commission/ 2023-04-06T10:01:35+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/04/logo-2.png https://www.nmsgroup.it/wp-content/uploads/2023/04/logo-2.png https://www.nmsgroup.it/nerviano-medical-sciences-announces-phase-1-clinical-trial-data-for-nms-03592088-in-patients-with-flt3-positive-relapsed-or-refractory-acute-myeloid-leukemia/ 2023-04-16T20:45:41+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/04/FLT3.png https://www.nmsgroup.it/nerviano-medical-sciences-selected-as-aacr-2023-planetary-session-highlights-for-its-nms-03592088-phase-1-clinical-trial-data-in-patients-with-flt3-positive-relapsed-or-refractory-acute-myeloid-leukem/ 2023-04-27T11:57:49+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/04/cover.png https://www.nmsgroup.it/wp-content/uploads/2023/04/IMG-20230419-WA0000.jpg https://www.nmsgroup.it/1st-european-cancer-dependency-map-symposium-successfully-concluded-in-milan-on-may-9th-sponsored-by-nerviano-medical-sciences-srl/ 2023-05-11T15:06:03+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/05/Immagine1-1-e1683817547700.png https://www.nmsgroup.it/wp-content/uploads/2023/05/IMG-20230509-WA0005.jpg https://www.nmsgroup.it/nerviano-medical-sciences-s-r-l-to-present-at-the-american-society-of-clinical-oncology-asco-2023-annual-meeting/ 2023-05-15T15:29:27+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/05/NMS153.png https://www.nmsgroup.it/nerviano-medical-sciences-appointed-paramjit-kaur-phd-to-accelerate-perk-gcn2-inhibitor-asset-development/ 2023-05-17T11:13:23+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/05/Pam.png https://www.nmsgroup.it/wp-content/uploads/2023/05/1679606724254.jpg https://www.nmsgroup.it/nerviano-medical-sciences-s-r-l-to-present-mpsa-153-001-at-asco-2023-slide-deck-poster-and-video-preview/ 2023-05-29T09:53:24+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/05/asco.png https://www.nmsgroup.it/nerviano-medical-sciences-announces-licensing-of-linker-payload-technology-to-solve-therapeutics-to-develop-and-commercialize-novel-antibody-drug-conjugates/ 2023-06-05T16:08:31+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/06/cover.png https://www.nmsgroup.it/nerviano-medical-sciences-announces-fda-clearance-of-investigational-new-drug-ind-for-nms-03592088-in-positive-relapsed-or-refractory-acute-myeloid-leukemia/ 2023-06-22T08:15:31+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/06/cover2.png https://www.nmsgroup.it/nerviano-medical-sciences-announces-enhanced-us-executive-team-terrence-west-mba-expands-role-as-chief-operating-officer/ 2023-08-01T15:41:36+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/08/Immagine1.png https://www.nmsgroup.it/visit-accelera-team-at-the-57th-congress-of-the-european-societies-of-toxicology-eurotox-2023-ljubljana-slovenia-september-10-13/ 2023-08-30T09:32:39+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/08/post.png https://www.nmsgroup.it/wp-content/uploads/2023/08/EUROTOX-2023-scaled.jpg https://www.nmsgroup.it/nerpharma-appoints-vittorio-montanaro-as-new-head-of-quality-to-strengthen-commitment-to-excellence/ 2023-09-01T06:00:52+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/08/cover.png https://www.nmsgroup.it/nerviano-medical-sciences-s-r-l-names-alberto-ocana-phd-as-global-clinical-lead/ 2023-09-11T09:52:45+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/09/imm.png https://www.nmsgroup.it/nerviano-medical-sciences-s-r-l-announces-preclinical-data-on-nms-p945-its-novel-proprietary-payload-linker-for-adc-generation-published-in-molecular-cancer-therapeutics/ 2023-09-20T12:38:24+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/09/cover-1.png https://www.nmsgroup.it/nerviano-medical-sciences-srl-partecipa-alla-european-biotech-week-2023-nerviano-medical-sciences-srl-participates-in-the-european-biotech-week-2023/ 2023-09-21T15:04:51+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/09/cover-2.png https://www.nmsgroup.it/wp-content/uploads/2023/09/Immagine1.png https://www.nmsgroup.it/nerviano-medical-sciences-s-r-l-to-present-data-on-its-adc-platform-at-the-world-adc-summit-2023-in-san-diego-ca-oct-16th-oct-19th-2023/ 2023-09-25T08:01:15+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/09/cover-3.png https://www.nmsgroup.it/alternative-method-developed-by-accelera-metodo-alternativo-sviluppato-da-accelera/ 2023-09-28T14:00:45+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/09/cover-4.png https://www.nmsgroup.it/wp-content/uploads/2023/09/20230921_111903-scaled.jpg https://www.nmsgroup.it/wp-content/uploads/2023/09/20230921_111851-scaled.jpg https://www.nmsgroup.it/nerviano-medical-sciences-to-present-preliminary-phase-1-parp1-selective-inhibitor-data-at-the-35th-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics/ 2023-10-04T07:57:35+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/10/cover.png https://www.nmsgroup.it/nerviano-medical-sciences-s-r-l-we-are-attending-the-2023-bio-europe-partnering-event-in-munich-germany/ 2023-10-09T13:37:22+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/10/cover-1.png https://www.nmsgroup.it/nerviano-medical-sciences-s-r-l-to-present-preliminary-phase-1-parp1-selective-inhibitor-data-at-the-35th-aacr-nci-eortc-2023-poster/ 2023-10-12T16:35:05+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/10/coverjpg.jpg https://www.nmsgroup.it/tiziano-lazzaretti-appointed-as-cfo-to-drive-financial-strategy-at-nms-srl/ 2023-11-02T04:00:05+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/10/cover.jpg https://www.nmsgroup.it/nms-srl-proudly-takes-part-of-the-mentoring-program-2024-organized-by-the-italian-chemical-society/ 2023-11-15T13:44:10+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/11/cover-1.png https://www.nmsgroup.it/wp-content/uploads/2023/11/apertura_tavolo_chimica_farmaceutica_3.png https://www.nmsgroup.it/wp-content/uploads/2023/11/apertura_tavolo_chimica_farmaceutica_4.png https://www.nmsgroup.it/nerpharma-appoints-claudio-salvagnini-as-deputy-ceo/ 2023-11-22T12:12:21+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/11/cover-2.png https://www.nmsgroup.it/serena-alvino-appointed-as-chief-legal-biotech-transaction-nms-srl-bringing-extensive-global-biopharmaceutical-experience/ 2023-12-04T09:37:57+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/12/serena-Alvino.png https://www.nmsgroup.it/nerviano-medical-sciences-and-italfarmaco-announce-licensing-of-linker-payload-technology-to-develop-and-commercialize-a-novel-peptide-drug-conjugate/ 2023-12-14T10:14:30+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/12/cover.png https://www.nmsgroup.it/nerviano-medical-sciences-srls-landmark-article-in-the-journal-of-organic-chemistry/ 2023-12-20T17:28:52+00:00 https://www.nmsgroup.it/wp-content/uploads/2023/12/cover2.png https://www.nmsgroup.it/wp-content/uploads/2023/12/Picture1.png https://www.nmsgroup.it/frontage-laboratories-acquires-accelera-s-r-l-s-bioanalytical-and-dmpk-businesses/ 2024-01-03T10:57:16+00:00 https://www.nmsgroup.it/wp-content/uploads/2024/01/cover.png https://www.nmsgroup.it/iktos-and-nerviano-medical-sciences-s-r-l-announce-collaboration-in-artificial-intelligence-for-new-drug-discovery/ 2024-01-08T09:45:51+00:00 https://www.nmsgroup.it/wp-content/uploads/2024/01/cover-1.png https://www.nmsgroup.it/nerviano-medical-sciences-received-orphan-drug-designation-for-its-next-generation-flt3-inhibitor-nms-03592088-for-treatment-of-acute-myeloid-leukemia/ 2024-01-09T13:57:14+00:00 https://www.nmsgroup.it/wp-content/uploads/2024/01/cover-2.png https://www.nmsgroup.it/new-european-patent-office-study-nms-srl-top-applicant-in-italy-during-the-2002-2021-period/ 2024-02-01T15:35:01+00:00 https://www.nmsgroup.it/wp-content/uploads/2024/02/1706744556863.jpg https://www.nmsgroup.it/nerviano-medical-sciences-received-european-medicines-agency-ema-orphan-drug-designation-for-its-next-generation-flt3-inhibitor-nms-03592088-for-treatment-of-acute-myeloid-leukemia/ 2024-03-04T14:40:03+00:00 https://www.nmsgroup.it/wp-content/uploads/2024/03/cover-240304-1.png https://www.nmsgroup.it/nerviano-medical-sciences-s-r-l-to-present-data-on-its-platform-of-payload-linkers-for-adc-conjugation-at-the-world-adc-summit-2024-in-london-uk-march-12th-15th-2024/ 2024-03-08T10:58:26+00:00 https://www.nmsgroup.it/wp-content/uploads/2024/03/ADC-London-24.png https://www.nmsgroup.it/nerviano-medical-sciences-s-r-l-presents-data-on-mps1-inhibitor-nms-153-and-on-adc-platform-at-the-aacr-annual-meeting-2024/ 2024-04-30T08:28:49+00:00 https://www.nmsgroup.it/wp-content/uploads/2024/04/AACR-2024-1.png https://www.nmsgroup.it/dr-frank-narjes-appointed-as-head-of-medicinal-chemistry-and-drug-design-elevating-innovation-at-nerviano-medical-sciences-srl/ 2024-05-13T09:51:02+00:00 https://www.nmsgroup.it/wp-content/uploads/2024/05/cover.png https://www.nmsgroup.it/nms-group-s-p-a-announced-new-board-of-directors-and-statutory-auditors/ 2024-05-28T12:19:07+00:00 https://www.nmsgroup.it/wp-content/uploads/2024/05/group2.jpg.png https://www.nmsgroup.it/nerviano-medical-sciences-announces-fda-protocol-clearance-of-new-ind-application-for-nms-812-a-first-in-class-dual-inhibitor-of-perk-gcn2-brian-sherer-phd-appointed-to-lead-and-accelerate-the-dev/ 2024-06-24T11:15:00+00:00 https://www.nmsgroup.it/wp-content/uploads/2024/06/cover.png https://www.nmsgroup.it/accelera-srl-announces-ceo-transition/ 2024-07-30T07:25:21+00:00 https://www.nmsgroup.it/simis-srl-appoints-marco-dieci-as-ceo-to-leverage-and-expand-further-opportunities-at-nerviano-bio-park/ 2024-09-02T08:41:30+00:00 https://www.nmsgroup.it/wp-content/uploads/2024/09/cover.png https://www.nmsgroup.it/nerpharma-appoints-vittorio-montanaro-as-new-industrial-operations-site-head-and-member-of-board-of-directors-to-fortify-our-commitment-to-excellence/ 2024-09-02T09:36:23+00:00 https://www.nmsgroup.it/wp-content/uploads/2024/09/cover-2.png https://www.nmsgroup.it/nerviano-medical-sciences-srl-announces-braftovi-royalty-agreement-with-blue-owl-capital-potentially-exceeding-80-million/ 2024-09-05T09:28:21+00:00 https://www.nmsgroup.it/nms-group-s-p-a-announces-change-in-shareholding-structure-board-of-directors-and-statutory-auditors-to-accelerate-growth-and-innovation/ 2024-09-11T07:45:50+00:00 https://www.nmsgroup.it/wp-content/uploads/2024/09/cover-3.png https://www.nmsgroup.it/nerviano-medical-sciences-announces-publication-of-the-paper-present-scenario-and-future-landscape-of-payloads-for-adcs-focus-on-dna-interacting-agents/ 2024-10-09T13:33:58+00:00 https://www.nmsgroup.it/wp-content/uploads/2024/10/ADC-rev_Valsasina-400x250-1.png https://www.nmsgroup.it/we-are-speaking-at-the-15th-annual-wadc-san-diego-2024/ 2024-10-09T14:00:18+00:00 https://www.nmsgroup.it/wp-content/uploads/2024/10/Nerviano-Medical-Sciences-banner-2.png https://www.nmsgroup.it/nerviano-medical-sciences-at-bio-europe-2024/ 2024-10-11T10:05:37+00:00 https://www.nmsgroup.it/wp-content/uploads/2024/10/bio-europe2024-1.png https://www.nmsgroup.it/cphi-worldwide-5/ 2024-10-11T10:10:04+00:00 https://www.nmsgroup.it/nerviano-medical-sciences-s-r-l-will-attend-the-swiss-biotech-day-2024-partnering-event-in-basel-switzerland/ 2024-10-11T10:10:04+00:00 https://www.nmsgroup.it/wp-content/uploads/2024/04/NMS_web.jpg https://www.nmsgroup.it/nerviano-medical-sciences-s-r-l-is-presenting-at-the-swiss-biotech-day-2024-in-basel/ 2024-10-11T10:10:04+00:00 https://www.nmsgroup.it/wp-content/uploads/2024/04/isacchi_swiss_web.png https://www.nmsgroup.it/we-are-speaking-at-the-3rd-global-xdc-innovation-conference-in-wuxi-china-2/ 2024-10-11T10:10:04+00:00 https://www.nmsgroup.it/wp-content/uploads/2024/08/cover1-1.png https://www.nmsgroup.it/wp-content/uploads/2024/08/We-are-speaking-at-2-1.png https://www.nmsgroup.it/nerviano-medical-sciences-will-be-exhibiting-at-the-sci-2024-xxviii-national-congress/ 2024-10-11T10:10:04+00:00 https://www.nmsgroup.it/wp-content/uploads/2024/08/cover-web.png https://www.nmsgroup.it/technological-innovations-in-medicinal-chemistry-the-continuous-flow-processes/ 2024-10-11T10:10:05+00:00 https://www.nmsgroup.it/elrig-forum/ 2024-10-11T10:10:05+00:00 https://www.nmsgroup.it/27th-protein-structure-determination-in-industry-meeting/ 2024-10-11T10:10:05+00:00 https://www.nmsgroup.it/17th-discovery-on-target-2019/ 2024-10-11T10:10:05+00:00 https://www.nmsgroup.it/esmo-2019/ 2024-10-11T10:10:05+00:00 https://www.nmsgroup.it/xxvi-nmmc-2019-nat-ional-meet-ing-in-medicinal-chemistry/ 2024-10-11T10:10:05+00:00 https://www.nmsgroup.it/15th-international-conference-on-malignant-lymphoma/ 2024-10-11T10:10:05+00:00 https://www.nmsgroup.it/16th-annual-meeting-of-the-bioinformatics-italian-society/ 2024-10-11T10:10:05+00:00 https://www.nmsgroup.it/slas-europe-2019/ 2024-10-11T10:10:05+00:00 https://www.nmsgroup.it/25-years-of-dna-encoded-chemistry-managing-serendipity-in-pre-clinical-small-molecule-drug-discovery-barry-morgan/ 2024-10-11T10:10:05+00:00 https://www.nmsgroup.it/16th-annual-meeting-of-the-bioinformatics-italian-society-2/ 2024-10-11T10:10:05+00:00 https://www.nmsgroup.it/glioma-in-2019-standard-of-care-of-idhwt-glioblastoma-and-idhmt-lower-grade-glioma-martin-van-den-bent/ 2024-10-11T10:10:05+00:00 https://www.nmsgroup.it/international-school-of-process-chemistry/ 2024-10-11T10:10:05+00:00 https://www.nmsgroup.it/terapie-personalizzate-nelle-neoplasie-mieloidi/ 2024-10-11T10:10:05+00:00 https://www.nmsgroup.it/15th-annual-pegs-boston/ 2024-10-11T10:10:06+00:00 https://www.nmsgroup.it/keystone-symposium-proteomics-and-its-application-to-translational-and-precision-medicine/ 2024-10-11T10:10:06+00:00 https://www.nmsgroup.it/257th-acs-national-meeting-exposition/ 2024-10-11T10:10:06+00:00 https://www.nmsgroup.it/aacr-2019/ 2024-10-11T10:10:06+00:00 https://www.nmsgroup.it/6th-cddd-meeting-computationally-driven-drug-discovery/ 2024-10-11T10:10:06+00:00 https://www.nmsgroup.it/3rd-world-conference-on-cancer-biology-and-immunology/ 2024-10-11T10:10:06+00:00 https://www.nmsgroup.it/the-physic-of-collective-cancer-migration/ 2024-10-11T10:10:06+00:00 https://www.nmsgroup.it/pre-clinical-mouse-models-and-breast-cancer-organoids-reveal-clues-to-therapeutic-resistance-and-disease-progression/ 2024-10-11T10:10:06+00:00 https://www.nmsgroup.it/pathology-lab-for-translational-medicine/ 2024-10-11T10:10:06+00:00 https://www.nmsgroup.it/treatment-options-in-high-risk-multiple-myeloma/ 2024-10-11T10:10:06+00:00 https://www.nmsgroup.it/targeting-acute-leukemia-by-lipid-antigen-specific-t-cells-restricted-for-cd1/ 2024-10-11T10:10:06+00:00 https://www.nmsgroup.it/ruolo-della-terapia-con-parp-inibitori-nel-trattamento-del-tumore-ovarico/ 2024-10-11T10:10:06+00:00 https://www.nmsgroup.it/global-medicinal-chemistry-gpcr-leaders-summit/ 2024-10-11T10:10:06+00:00 https://www.nmsgroup.it/european-molecular-biology-laboratory-conference/ 2024-10-11T10:10:06+00:00 https://www.nmsgroup.it/xix-congresso-nazionale-aiom/ 2024-10-11T10:10:07+00:00 https://www.nmsgroup.it/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-discovery-biology-and-clinical-applications/ 2024-10-11T10:10:07+00:00 https://www.nmsgroup.it/imi-k4dd-conference-2017-binding-kinetics-time-is-of-the-essence/ 2024-10-11T10:10:07+00:00 https://www.nmsgroup.it/xxxv-conferenza-nazionale-di-citometria/ 2024-10-11T10:10:07+00:00 https://www.nmsgroup.it/cancer-bio-immunotherapy-xv-nibit-meeting/ 2024-10-11T10:10:07+00:00 https://www.nmsgroup.it/8th-world-adc-congress/ 2024-10-11T10:10:07+00:00 https://www.nmsgroup.it/40-congress-of-the-european-society-of-medical-oncology/ 2024-10-11T10:10:07+00:00 https://www.nmsgroup.it/eacr-aacr-sicthe-challenges-of-optimising-immuno-and-targeted-therapies-from-cancer-biology-to-clinic/ 2024-10-11T10:10:07+00:00 https://www.nmsgroup.it/18th-annual-drug-discovery-summit/ 2024-10-11T10:10:07+00:00 https://www.nmsgroup.it/vii-congresso-nazionale-organizzato-da-ismrm-italian-chapter/ 2024-10-11T10:10:07+00:00 https://www.nmsgroup.it/aacr-2017/ 2024-10-11T10:10:07+00:00 https://www.nmsgroup.it/fragments-2017-6th-rsc-bmcs-fragment-based-drug-discovery-meeting/ 2024-10-11T10:10:07+00:00 https://www.nmsgroup.it/er-stress-autophagy-immune-system/ 2024-10-11T10:10:07+00:00 https://www.nmsgroup.it/nerviano-medical-sciences-announces-strategic-acquisition-of-atamparib-a-phase-ii-ready-parp7-inhibitor-from-ribon-therapeutics/ 2024-11-14T08:46:06+00:00 https://www.nmsgroup.it/wp-content/uploads/2024/11/atamparib-202411.png https://www.nmsgroup.it/nerviano-medical-sciences-nms-to-reacquire-world-wide-rights-of-nms-293-a-potent-highly-selective-non-trapping-brain-penetrant-parp1-inhibitor-with-promising-clinical-results/ 2024-11-25T15:04:58+00:00 https://www.nmsgroup.it/wp-content/uploads/2024/11/cover.png https://www.nmsgroup.it/nerviano-medical-sciences-s-r-l-announces-the-launch-of-a-new-clinical-trial-to-evaluate-nms-153-in-combination-with-atezolizumab-and-clinical-trial-supply-agreement-with-roche/ 2025-01-07T11:33:11+00:00 https://www.nmsgroup.it/wp-content/uploads/2025/01/nms-153-atez_cover2.png https://www.nmsgroup.it/nerviano-medical-sciences-announces-fda-clearance-of-two-inds-for-its-parp1-selective-non-trapping-inhibitor-nms-293-to-start-clinical-studies-in-small-cell-lung-cancer-and-brca-wild-type-ovarian-car/ 2025-01-13T10:08:20+00:00 https://www.nmsgroup.it/wp-content/uploads/2025/01/PARP1_2IND.png https://www.nmsgroup.it/nerviano-medical-sciences-is-presenting-at-the-8th-annual-ddr-inhibitors-summit/ 2025-01-30T18:13:36+00:00 https://www.nmsgroup.it/wp-content/uploads/2025/01/cover-final.png https://www.nmsgroup.it/8th-ddr-inhibitors-summit-presentation/ 2025-01-30T20:45:15+00:00 https://www.nmsgroup.it/wp-content/uploads/2025/01/TK.jpg https://www.nmsgroup.it/wp-content/uploads/2025/01/presentation-cover.png https://www.nmsgroup.it/nerviano-medical-sciences-presentation-from-the-8th-annual-ddr-inhibitors-summit-is-now-available/ 2025-01-31T09:40:56+00:00 https://www.nmsgroup.it/wp-content/uploads/2025/01/cover.png https://www.nmsgroup.it/parp1-publications/ 2025-02-11T08:21:01+00:00 https://www.nmsgroup.it/wp-content/uploads/2025/02/NMS-small.jpg https://www.nmsgroup.it/wp-content/uploads/2025/01/presentation-cover.png https://www.nmsgroup.it/wp-content/uploads/2025/02/ref14.jpg https://www.nmsgroup.it/wp-content/uploads/2025/02/ref14poster.jpg https://www.nmsgroup.it/wp-content/uploads/2025/02/ref12.jpg https://www.nmsgroup.it/wp-content/uploads/2025/02/ref11.jpg https://www.nmsgroup.it/wp-content/uploads/2025/02/REF9.jpg https://www.nmsgroup.it/wp-content/uploads/2025/02/ref1a.png https://www.nmsgroup.it/wp-content/uploads/2025/02/ref1b.png https://www.nmsgroup.it/wp-content/uploads/2025/02/ref1f.png https://www.nmsgroup.it/wp-content/uploads/2025/02/ref1g.png https://www.nmsgroup.it/wp-content/uploads/2025/02/ref20.jpg https://www.nmsgroup.it/wp-content/uploads/2025/02/ref21.jpg https://www.nmsgroup.it/wp-content/uploads/2025/02/ref22.jpg https://www.nmsgroup.it/wp-content/uploads/2025/02/ref23.jpg https://www.nmsgroup.it/wp-content/uploads/2025/02/ref24.jpg https://www.nmsgroup.it/wp-content/uploads/2025/02/ref26-1.jpg https://www.nmsgroup.it/wp-content/uploads/2025/02/ref27.jpg https://www.nmsgroup.it/wp-content/uploads/2025/02/ref1c.png https://www.nmsgroup.it/wp-content/uploads/2025/02/ref1d.png https://www.nmsgroup.it/wp-content/uploads/2025/02/ref25.jpg https://www.nmsgroup.it/wp-content/uploads/2025/02/ref1e.png https://www.nmsgroup.it/wp-content/uploads/2025/02/ref1i.png https://www.nmsgroup.it/wp-content/uploads/2025/02/ref1h.png https://www.nmsgroup.it/wp-content/uploads/2025/02/ref18.jpg https://www.nmsgroup.it/wp-content/uploads/2025/02/ref17.jpg https://www.nmsgroup.it/wp-content/uploads/2025/02/ref19.jpg https://www.nmsgroup.it/wp-content/uploads/2025/02/ref16.jpg https://www.nmsgroup.it/wp-content/uploads/2025/02/ref15.jpg https://www.nmsgroup.it/nerviano-medical-sciences-srl-announces-rozlytrek-entrectinib-royalty-agreement/ 2025-04-02T09:38:07+00:00 https://www.nmsgroup.it/wp-content/uploads/2025/03/PR-entr-1.png https://www.nmsgroup.it/nerviano-medical-sciences-initiates-combination-phase-1-trials-of-nms-293-in-relapsed-small-cell-lung-and-brca-wild-type-ovarian-cancers/ 2025-04-28T14:24:28+00:00 https://www.nmsgroup.it/wp-content/uploads/2025/04/PARP_SCLC_Ovarian.png https://www.nmsgroup.it/nms-group-s-p-a-appoints-victor-chu-to-board-of-directors/ 2025-07-10T07:24:17+00:00 https://www.nmsgroup.it/wp-content/uploads/2025/07/Victor-Chu.png https://www.nmsgroup.it/nerviano-medical-sciences-srl-announces-its-plan-to-focus-its-portfolio-on-three-biological-targets-and-adc-platform/ 2025-07-23T13:33:45+00:00 https://www.nmsgroup.it/wp-content/uploads/2025/07/comm.png https://www.nmsgroup.it/accelera-appoints-silvia-guionaud-phd-decvp-as-chief-executive-officer/ 2025-07-28T16:31:06+00:00 https://www.nmsgroup.it/wp-content/uploads/2025/07/Acc-Silvia.png https://www.nmsgroup.it/bionerviano-srl-appoints-serena-alvino-as-chief-executive-officer/ 2025-07-28T16:31:12+00:00 https://www.nmsgroup.it/wp-content/uploads/2025/07/Bio-N-Serena.png https://www.nmsgroup.it/nerpharma-appoints-serena-alvino-as-chief-executive-officer/ 2025-07-28T16:31:20+00:00 https://www.nmsgroup.it/wp-content/uploads/2025/07/NPM-Serena.png https://www.nmsgroup.it/science-democracy-and-animal-experimentation-the-need-for-a-debate-sept-13th-2-30-3-30-pm/ 2025-07-28T16:50:02+00:00 https://www.nmsgroup.it/wp-content/uploads/2022/09/Immagine2.png https://www.nmsgroup.it/wp-content/uploads/2022/09/Immagine2.png https://www.nmsgroup.it/wp-content/uploads/2020/12/Code-of-Ethics-nms-group.pdf https://www.nmsgroup.it/nerviano-medical-sciences-srl-launches-china-subsidiary-to-advance-oncology-pipeline-and-adc-portfolio/ 2025-08-01T08:17:45+00:00 https://www.nmsgroup.it/wp-content/uploads/2025/07/comm.png https://www.nmsgroup.it/cphi-frankfurt-2025/ 2025-09-11T08:53:01+00:00 https://www.nmsgroup.it/wp-content/uploads/2025/09/CPhI-2025-scaled-1.png https://www.nmsgroup.it/cphi-worldwide-3/ 2025-09-11T09:02:05+00:00 https://www.nmsgroup.it/dcat-week-2025/ 2025-09-11T09:02:05+00:00 https://www.nmsgroup.it/wp-content/uploads/2025/02/DCAT-2025-1.png https://www.nmsgroup.it/wp-content/uploads/2025/02/DCAT-2025-1.png https://www.nmsgroup.it/nms-adc-poster-and-presentation-novel-cytotoxin-and-targeted-payload-platforms-at-festival-of-biologics/ 2025-10-02T09:25:58+00:00 https://www.nmsgroup.it/wp-content/uploads/2025/10/festival-of-biologics-2025.png https://www.nmsgroup.it/wp-content/uploads/2025/10/Picture1.jpg https://www.nmsgroup.it/wp-content/uploads/2025/10/shared-image-1.jpg https://www.nmsgroup.it/wp-content/uploads/2025/10/shared-image.jpg https://www.nmsgroup.it/wp-content/uploads/2025/10/shared-image-2.jpg https://www.nmsgroup.it/nerviano-medical-sciences-srl-announces-participation-in-bio-europe-2025/ 2025-10-27T14:12:47+00:00 https://www.nmsgroup.it/wp-content/uploads/2025/10/Bioeurope2025.png https://www.nmsgroup.it/nerviano-medical-sciences-presented-data-on-novel-payload-linkers-for-adc-conjugation-at-the-world-adc-summit-2025/ 2025-11-07T13:53:24+00:00 https://www.nmsgroup.it/wp-content/uploads/2025/11/WADC_poster.png https://www.nmsgroup.it/nerviano-medical-sciences-nms-china-joins-roche-accelerator-to-advance-oncology-innovation/ 2025-11-17T09:48:33+00:00 https://www.nmsgroup.it/wp-content/uploads/2025/11/NMS.png https://www.nmsgroup.it/nerviano-medical-sciences-announces-nmpa-clearance-of-ind-for-parp7-selective-inhibitor-atamparib-in-promising-new-therapeutic-setting/ 2026-01-15T16:02:29+00:00 https://www.nmsgroup.it/wp-content/uploads/2026/01/ATA-IND.png https://www.nmsgroup.it/benta-strengthens-its-european-presence-with-the-acquisition-of-the-italian-cdmo-nerpharma-in-milan/ 2026-02-18T15:07:40+00:00 https://www.nmsgroup.it/wp-content/uploads/2026/02/NPM-cover.png